



BAFNA PHARMACEUTICALS LIMITED

Regd. Office, No.299, Thambu Chetty Street, Chennai-600 001. Tel.No. 044-42677555 / Fax No. 044-42677599

ONE TEAM ONE DREAM - RARICAP No. 1

With Global Success, **BAFNA PHARMACEUTICALS LIMITED** has now entered the domestic arena by acquiring a **PRESTIGIOUS** and a **SUCCESSFUL**, Time Tested 40 year old brand '**RARICAP**' marketed by M/s Johnson and Johnson Limited and is determined to continue the legacy of '**RARICAP**'.

Raricap* Forte



Raricap*



Raricap* L



Raricap* Combi



Sales up by
36.16%

Net Profit up by
74.12%

AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31st MARCH 2011

(Rs. In Lakhs)

No	PARTICULARS	Quarter Ended		Year Ended	
		31.03.2011 (Audited)	31.03.2010 (Audited)	31.03.2011 (Audited)	31.03.2010 (Audited)
1	INCOME				
a	Sales	2960.21	2407.62	10130.32	7440.14
b	Other Operating Income	0.00	0.00	0.00	0.00
	Total Income (a+b)	2960.21	2407.62	10130.32	7440.14
2	EXPENDITURE				
a	(Increase) / Decrease in Stock in Trade & Work in Progress	(74.34)	517.95	(243.43)	(81.91)
b	Consumption of Raw materials	2613.94	1676.89	8627.42	6297.42
c	Purchase of Traded Goods	0.00	0.00	0.00	0.00
d	Employee Cost	95.04	43.98	309.13	235.30
e	Depreciation	54.69	42.00	226.59	173.79
f	Other Expenditure	100.27	53.24	319.03	209.70
	Total	2789.60	2334.06	9238.73	6834.30
3	Profit from Operations before Other Income, Interest and Exceptional Items (1-2)	170.61	73.56	891.58	605.84
4	Other Income	15.46	27.90	62.10	77.99
5	Profit before Interest and exceptional Items (3+4)	186.07	101.46	953.69	683.83
6	Interest & Bank Charges	121.54	-3.21	429.63	231.86
7	Profit(+)/Loss(-) after Interest but before Tax	64.53	104.67	524.05	451.97
8	Exceptional items (5-6)				
8	Exceptional items	11.38	12.96	50.28	55.44
9	Profit(+)/Loss(-) from Ordinary Activities before tax (7-8)	53.15	91.71	473.77	396.53
10	Tax Expenses	0.00	148.38	138.97	148.38
11	Net Profit(+)/Loss(-) from Ordinary Activities After Tax (9-10)	53.15	(56.67)	334.80	248.15
12	Extraordinary Items	0.00	0.00	0.00	0.00
13	Net Profit(+)/Loss(-) for the period (11-12)	53.15	(56.67)	334.80	248.15
14	Paid up Equity Share Capital (Rs.)	1748.13	1598.13	1748.13	1598.13
	Face Value of the Share (Rs.)	10.00	10.00	10.00	10.00
15	Reserves excluding Revaluation Reserves as per Balance Sheet of previous Accounting Year	0.00	0.00	3368.06	2502.33
16	Earnings per Share (EPS) :				
a	Basic and diluted EPS Before Extraordinary Items	0.30	(0.35)	2.71	1.55
b	Basic and diluted EPS After Extraordinary Items	0.30	(0.35)	1.92	1.55
17	Public Share Holding :				
	Number of Shares	10283853	7940392	10283853	7940392
	Percentage of Share Holding	58.83	49.69	58.83	49.69
18	Promoters and promoter group				
a	Pledged/Encumbered				
	Number of Shares	450000	NIL	450000	NIL
	Percentage of shares (as a % of the total share holding of promoter and promoter group)	6.25	NIL	6.25	NIL
	Percentage of shares (as a % of the total share capital of the company)	2.57	NIL	2.57	NIL
b	Non-encumbered				
	Number of Shares	6747482	8040943	6747482	8040943
	Percentage of shares (as a % of the total share holding of promoter and promoter group)	93.75	100.00	93.75	100.00
	Percentage of shares (as a % of the total share capital of the company)	38.60	50.31	38.60	50.31

NOTES

- The above audited quarterly financial results were reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on 30.05.2011
- The Company operates only in one segment, ie. Pharmaceutical formulations, as such reporting is done on a single segment basis.
- The figures for the previous periods have been regrouped wherever necessary.
- Status of investor Complaints.:

Opening balance	Nil
Pending at the beginning of the quarter	Nil
No. of complaints received and disposed off during the quarter	Nil
Complaints pending at the end of the quarter	Nil

Place: Chennai
Date : 30.05.2011

For and on behalf of the Board of Directors,
Sd/-
BAFNA MAHAVEER CHAND
Managing Director